NewsBenzinga阿斯利康已达成协议，将向 Summit Therapeutics 新发行股份投资 20 亿美元，以加速推进首创双特异性抗体 ivonescimab 的开发；该抗体靶向 PD-1 和 VEGF，并将与抗体药物偶联物联合用于多种肿瘤类型；同时，Summit 与阿斯利康还签署了临床合作协议，评估 sonesitatug vedotin 与 ivonescimab 的联用。 阿斯利康已达成协议，将向 Summit Therapeutics 新发行股份投资 20 亿美元，以加速推进首创双特异性抗体 ivonescimab 的开发；该抗体靶向 PD-1 和 VEGF，并将与抗体药物偶联物联合用于多种肿瘤类型；同时，Summit 与阿斯利康还签署了临床合作协议，评估 sonesitatug vedotin 与 ivonescimab 的联用。 Benzinga 2026.09.28 21:37 (GMT+0) Open on Benzinga Other news Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.04 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $15.1 Billion CoreWeave’s CEO Says the Market Doesn’t Understand His Company. Whether or Not It Does Isn’t What Matters Here. Chevron Stock Price Targets Are Up and Put Credit Spreads Are Attractive to Value Players Traders Give Google a 70% Chance of Having the Best AI Model. Most People Can’t Even Use It Yet. Apple updates guidelines to ban nudify apps masquerading as regular apps to pass review Ahead of General Motors Earnings, Here's What Barchart Data Says Comes Next for GM Stock
Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.04 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $15.1 Billion
CoreWeave’s CEO Says the Market Doesn’t Understand His Company. Whether or Not It Does Isn’t What Matters Here.
